1. Lerner AB, Watson CJ: Studies of cryoglobulins. II. The spontaneous precipitation of protein from serum at 5ºC in various disease states. Am J Med Sci 214:416, 1947
2. Brouet JC et al: Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57:775-788, 1974
3. Lunel F et al: Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage. Gastroenterology 106:1291-1300, 1994
4. Pawlotsky JM et al: Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 19:841-848, 1994
5. Santagostino E et al: High prevalence of serum cryoglobulins in multitransfused hemophilic patients with chronic hepatitis C. Blood 92:516-519, 1998
6. Lapinski TW et al: Prevalence of cryoglobulinaemia in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected individuals: implications for renal function. Liver Int 29:1158-1161, 2009
7. Cacoub P et al: Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 42:2204-2212, 1999
8. Cacoub P et al: Cryoglobulinemia vasculitis. Curr Opin Rheumatol 14:29-35, 2002
9. Fiorentino DF: Cutaneous vasculitis. J Am Acad Dermatol 48:311-340, 2003
10. Armstrong GL et al: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705-714, 2006
11. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 345:41-52, 2001
12. Ferri C: Mixed cryoglobulinemia. Orphanet J Rare Dis 3:25, 2008
13. Wintrobe M, Buell M: Hyperproteinemia associated with multiple myeloma. With report of a case in which an extraordinary hyperproteinemia was associated with thrombosis of the retinal veins and symptoms suggesting Raynaud's disease. Bull Johns Hopkins Hosp 52:156-165, 1933
14. Zinneman HH: Cryoglobulins and pyroglobulins. Pathobiol Annu 10:83-104, 1980
15. Tissot JD et al: Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide. J Immunol Methods 173:63-75, 1994
16. Cacoub P et al: Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum 44:2118-2124, 2001
17. Sebastiani GD et al: Association of extrahepatic manifestations with HLA class II alleles and with virus genotype in HCV infected patients. J Biol Regul Homeost Agents 19:17-22, 2005
18. Charles ED, Dustin LB: Hepatitis C virus-induced cryoglobulinemia. Kidney Int 76:818-824, 2009
19. Monti G et al: Cryoglobulinaemias: A multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 88:115-126, 1995
20. Saadoun D et al: Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 166:2101-2108, 2006
21. Sene D et al. Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J Rheumatol 31:2199-2206, 2004
22. Vallat L et al: Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 50:3668-3678, 2004
23. Levo Y et al: Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med 296:1501-1504, 1977
24. Dimitrakopoulos AN et al: Mixed cryoglobulinemia in HIV-1 infection: The role of HIV-1. Ann Intern Med 130:226-230, 1999
25. Chiche L et al: Mixed cryoglobulinemia: A role for parvovirus b19 infection. Clin Infect Dis 50:1074-1075, 2010
26. Ramos-Casals M et al: Cutaneous vasculitis in primary Sjogren syndrome: Classification and clinical significance of 52 patients. Medicine (Baltimore) 83:96-106, 2004
27. Ramos-Casals M et al: Cryoglobulinemia in primary Sjogren's syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 28:200-205, 1998
28. Garcia-Carrasco M et al: Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Semin Arthritis Rheum 30:366-373, 2001
29. Ferri C et al: Mixed cryoglobulinemia: Demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 33:355-374, 2004
30. Perico N et al: Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 4:207-220, 2009
31. Hent RC et al: Delayed onset of membranoproliferative glomerulonephritis in a patient with type I cryoglobulinaemia. Nephrol Dial Transplant 12:2155-2158, 1997
32. Kamar N, Rostaing L, Alric L: Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 69:436-439, 2006
33. Johnson RJ et al: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328:465-470, 1993.
34. Johnson RJ, Feehally J. Comprehensive Clinical Nephrology Edinburgh, New York, Mosby, 2003
35. Fornasieri A et al: High binding of immunoglobulin M kappa rheumatoid factor from type II cryoglobulins to cellular fibronectin: A mechanism for induction of in situ immune complex glomerulonephritis? Am J Kidney Dis 27:476-483, 1996
36. Roccatello D et al; Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 49:69-82, 2007
37. Fabrizi F et al: Kidney and liver involvement in cryoglobulinemia. Semin Nephrol 22:309-318, 2002
38. Beddhu S, Bastacky S, Johnson JP: The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 81:398-409, 2002
39. Antonelli A et al: Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology (Oxford) 43:238-240, 2004
40. Vitali C et al: Hypercomplementaemia as a marker of the evolution from benign to malignant B cell proliferation in patients with type II mixed cryoglobulinaemia. Br J Rheumatol 33:791-792, 1994
41. Antonelli A et al: Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia. Arthritis Rheum 60:3841-3847, 2009
42. Antonelli A et al: Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. J Rheumatol 37:91-97, 2009
43. Sansonno D et al: Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. Blood 112:1620-1627, 2008
44. Monti G, Saccardo F: Emergency in cryoglobulinemic syndrome: What to do? Dig Liver Dis 39(Suppl. 1):S112-S115, 2007
45. Della Rossa A et al: Mixed cryoglobulinemia and mortality: A review of the literature. Clin Exp Rheumatol 26:S105-S108, 2008
46. Saccardo E et al: Causes of death in symptomatic cryoglobulinemia: 30 years of observation in a Department of Internal Medicine. Dig Liver Dis 39(Suppl. 1):S52-S54, 2007
47. Landau DA et al: Causes and predictive factors of mortality in a cohort of patients with hepatitis c virus-related cryoglobulinemic vasculitis treated with antiviral therapy. J Rheumatol 37:615-621, 2010
48. Bruchfeld A et al: Interferon and
ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency.
Nephrol Dial Transplant 18:1573-1580, 2003
49. Sabry AA et al: Effect of combination therapy (
ribavirin and interferon) in HCV-related glomerulopathy.
Nephrol Dial Transplant 17:1924-1930, 2002
50. Gorevic PD et al: Mixed cryoglobulinemia: Clinical aspects and long-term follow-up of 40 patients. Am J Med 287-308, 1980
51. Matignon M et al: Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Medicine (Baltimore) 88:341-348, 2009
52. Cacoub P et al: PEGylated interferon alfa-2b and
ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Arthritis Rheum 52:911-915, 2005
53. Saadoun D et al: Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: A long-term followup study. Arthritis Rheum 54:3696-3706, 2006
54. Saadoun D et al:
Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
Ann Rheum Dis 67:1431-1436, 2008
55. Cacoub P et al: PEGylated interferon alfa-2b and
ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Arthritis Rheum 52:911-915, 2005
56. Cacoub P et al: Interferon-alpha and
ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Arthritis Rheum 46:3317-3326, 2002
57. Casato M et al: Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 90:3865-3873, 1997
58. Dammacco F et al: Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: A long-term, randomized, controlled study. Blood 84:3336-3343, 1994
59. Mazzaro C et al: Treatment with peg-interferon alfa-2b and
ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: A pilot study.
J Hepatol 42:632-638, 2005
60. Misiani R et al: Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330:751-756, 1994
61. Naarendorp M et al: Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 28:2466-2473, 2001
62. Saadoun D et al: Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: A long-term followup study. Arthritis Rheum 54:3696-3706, 2006
63. Zuckerman E et al: Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with
ribavirin and interferon-alpha.
J Rheumatol 27:2172-2178, 2000
64. Dienstag JL, McHutchison JG: American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130:231-264, 2006; quiz 214-217
65. Dienstag JL, McHutchison JG: American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 130:225-230, 2006
66. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl (109):S1-S99, 2008
67. Bruchfeld A et al: Dosage of
ribavirin in patients with hepatitis C should be based on renal function: A population pharmacokinetic analysis.
Ther Drug Monit 24:701-708, 2002
68. Saadoun D et al: Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 20:23-28, 2008
69. Cacoub P et al: Anti-CD20 monoclonal antibody (
rituximab) treatment for cryoglobulinemic vasculitis: Where do we stand?
Ann Rheum Dis 67:283-287, 2008
70. Sansonno D et al: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818-3826, 2003
71. Garini G et al: Successful treatment of severe/active cryoglobulinaemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection by means of the sequential administration of immunosuppressive and antiviral agents. Nephrol Dial Transplant 21:3333-3334, 2006
72. Saadoun D et al:
Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
Ann Rheum Dis 67:1431-1436, 2008
73. Sene D et al:
Rituximab may form a complex with IgM kappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
Arthritis Rheum 60:3848-3855, 2009
74. Landau DA et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 58:604-611, 2008
75. Saadoun D et al: Cryofibrinogenemia: new insights into clinical and pathogenic features. Am J Med 122:1128-1135, 2009
76. Belizna CC et al: Outcome of essential cryofibrinogenaemia in a series of 61 patients. Rheumatology (Oxford) 47:205-207, 2008
77. Korst DR, Kratochvil CH: Cryofibrinogen in a case of lung neoplasm associated with thrombophlebitis migrans. Blood 10:945-953, 1955
78. Blain H et al. Cryofibrinogenaemia: A study of 49 patients. Clin Exp Immunol 120:253-260, 2000
79. Delluc A et al: Cryofibrinogen in patients with hepatitis C virus infection. Am J Med 121:624-631, 2008
80. Singh A, Gaber LW: Nephrotic syndrome and chronic renal insufficiency associated with essential cryofibrinogenemia. Nephrol Dial Transplant 22:1772-1775, 2007
81. McGrath MA et al: Systemic factors contributory to retinal vein occlusion. Arch Intern Med 138:216-220, 1978
82. Nash JW et al: The histopathologic spectrum of cryofibrinogenemia in four anatomic sites. Skin, lung, muscle, and kidney. Am J Clin Pathol 119:114-122, 2003
83. Lee J et al: Cryofibrinogenemia in a patient with B-cell lymphoma. Clin Lymphoma 1:234-237, 2000; discussion 238-9.
84. Kirsner RS et al: Stanozolol causes rapid pain relief and healing of cutaneous ulcers caused by cryofibrinogenemia. J Am Acad Dermatol 28:71-74, 1993
85. Chartier M, Falanga V. Healing of ulcers due to cryofibrinogenemia with
colchicine and high-dose
pentoxifylline.
Am J Clin Dermatol 10:39-42, 2009
86. Euler HH et al: Monoclonal cryo-antifibrinogenemia. Arthritis Rheum 39:1066-1069, 1996